Matthew Wheater

Matthew Wheater

Auto-generated profile, based on publicly available information

Matthew Wheater

University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2016 in Oncotarget
Verified
Journal Article
Open access
CLCristian Lolli
Cristian Lolli
UBUmberto Basso
Umberto Basso
LDLisa Derosa
Lisa Derosa
ESEmanuela Scarpi
Emanuela Scarpi
TSTeodoro Sava
Teodoro Sava
UGUgo De Giorgi
Ugo De Giorgi
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

1 September 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
EAEdurne Arriola
Edurne Arriola
MWMatthew Wheater
Matthew Wheater
IGIan Galea
Ian Galea
NCNadia Cross
Nadia Cross
TMTom Maishman
Tom Maishman
COChristian H. Ottensmeier
Christian H. Ottensmeier
Our aim was to evaluate the safety and efficacy of ipilimumab combined with standard first-line chemotherapy for patients with extensive-stage SCLC. Patients with chemotherapy-naive extensive-stage SCLC were treated with carboplatin and etoposide for up to six cycles. Ipilimumab, 10 mg/kg, was given on day 1 of cycles 3 to 6 and every 12 weeks. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, and immune-related response criteria. The primary end point was 1-year progression-free survival (PFS) according to RECIST. Secondary end points included PFS according to immune-related PFS and overall survival. Autoantibody serum levels were evaluated and correlated with clinical outcomes. A total of 42 patients were enrolled between September 2011 and April 2014; 39 were evaluable for safety and 38 for efficacy. Six of 38 patients (15.8% [95% confidence interval (CI): 7.4-30.4]) were alive and progression-free at 1-year by RECIST. Median PFS was 6.9 months (95% CI: 5.5-7.9). Median immune-related PFS was 7.3 months (95% CI: 5.5-8.8). Median overall survival was 17.0 months (95% CI: 7.9-24.3). Of the patients evaluable for response, 21 of 29 (72.4%) achieved an objective response by RECIST and 28 of 33 (84.8%) achieved an objective response by the immune-related response criteria. All patients experienced at least one adverse event; at least one grade 3 or higher toxicity developed in 35 of 39 patients (89.7%); in 27 patients (69.2%) this was related to ipilimumab. Five deaths were reported to be related to ipilimumab. Positivity of an autoimmune profile at baseline was associated with improved outcomes and severe neurological toxicity. Ipilimumab in combination with carboplatin and etoposide might benefit a subgroup of patients with advanced SCLC. Autoantibody analysis correlates with treatment benefit and toxicity and warrants further investigation.

1 March 2016 in European Urology
Verified
Journal Article
Closed access
TPThomas Powles
Thomas Powles
MWMatthew Wheater
Matthew Wheater
ODOmar Din
Omar Din
TGThomas Geldart
Thomas Geldart
EBEkaterini Boleti
Ekaterini Boleti
CRChristy Ralph
Christy Ralph

18 February 2016 in OncoImmunology
Verified
Journal Article
Open access
IKIoannis Karydis
Ioannis Karydis
PCPui Ying Chan
Pui Ying Chan
MWMatthew Wheater
Matthew Wheater
EAEdurne Arriola
Edurne Arriola
PSPeter W. Szlosarek
Peter W. Szlosarek
COChristian H. Ottensmeier
Christian H. Ottensmeier
Background: Untreated metastatic uveal melanoma (UM) carries a grave prognosis. Unlike cutaneous melanoma (CM), there are no established treatments known to significantly improve outcomes for a meaningful proportion of patients. Inhibition of the PD1–PDL1 axis has shown promise in the management of CM and we here report a two center experience of UM patients receiving pembrolizumab. Methods: To assess the efficacy and safety of pembrolizumab, we retrospectively analyzed outcome data of 25 consecutive UM patients participating in the MK3475 expanded access program (EAP) who received pembrolizumab at 2 mg/kg 3 weekly. Tumor assessment was evaluated using RECIST 1.1 and immune-related Response Criteria (irRC) by CT scanning. Toxicity was recorded utilizing Common Terminology Criteria for Adverse Events (“CTCAE”) v4.03. Results: Twenty-five patients were identified receiving a median of six cycles of treatment. Two patients achieved a partial response and six patients stable disease. After a median follow-up of 225 d median progression free survival (PFS) was 91 d and overall survival (OS) was not reached. There was a significant trend for improved outcomes in patients with extrahepatic disease progression as opposed to liver only progression at the outset. Five patients experienced grade 3 or 4 adverse events (AEs); there were no treatment related deaths. Conclusions: Pembrolizumab 2mg/kg q3w is a safe option in UM patients. Disease control rates, particularly in the subgroup of patients without progressive liver disease at the outset are promising; these results merit further investigation in clinical trials possibly incorporating liver targeted treatment modalities.

28 December 2017 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
IKIoannis Karydis
Ioannis Karydis
AGAlexandra Gangi
Alexandra Gangi
MWMatthew J. Wheater
Matthew J. Wheater
JCJunsung Choi
Junsung Choi
IWIain Wilson
Iain Wilson
COChristian H. Ottensmeier
Christian H. Ottensmeier
Background: Metastatic uveal melanoma (UM) carries a poor prognosis; liver is the most frequent and often solitary site of recurrence. Available systemic treatments have not improved outcomes. Melphalan percutaneous hepatic perfusion (M‐PHP) allows selective intrahepatic delivery of high dose cytotoxic chemotherapy.Methods: Retrospective analysis of outcomes data of UM patients receiving M‐PHP at two institutions was performed. Tumor response and toxicity were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events (CTCAE) v4.03, respectively.Results: A total of 51 patients received 134 M‐PHP procedures (median of 2 M‐PHPs). 25 (49%) achieved a partial (N = 22, 43.1%) or complete hepatic response (N = 3, 5.9%). In 17 (33.3%) additional patients, the disease stabilized for at least 3 months, for a hepatic disease control rate of 82.4%. After median follow‐up of 367 days, median overall progression free (PFS) and hepatic progression free survival (hPFS) was 8.1 and 9.1 months, respectively and median overall survival was 15.3 months. There were no treatment related fatalities. Non‐hematologic grade 3‐4 events were seen in 19 (37.5%) patients and were mainly coagulopathic (N = 8) and cardiovascular (N = 9).Conclusions: M‐PHP results in durable intrahepatic disease control and can form the basis for an integrated multimodality treatment approach in appropriately selected UM patients.

14 December 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EAEdurne Arriola
Edurne Arriola
MWMatthew Wheater
Matthew Wheater
IKIoannis Karydis
Ioannis Karydis
GTGareth Thomas
Gareth Thomas
COChristian H. Ottensmeier
Christian H. Ottensmeier